Navigation Links
Detecting glaucoma before it blinds
Date:10/6/2011

Early detection and diagnosis of open angle glaucoma important so that treatment can be used in the early stages of the disease developing to prevent or avoid further vision loss. Writing in a forthcoming issue of the International Journal of Medical Engineering and Informatics, researchers in the US have analyzed and ranked the various risk factors for open angle glaucoma so that patients can be screened at an earlier stage if they are more likely to develop the condition.

Glaucoma is one of the main leading causes of blindness; it is a progressive and irreversible disease. Of the various forms of glaucoma, open angle glaucoma (OAG) is the most common and can cause the most damage. Unfortunately, unless a patient is undergoing regular screening from about the age of 40 years because of a family history, it is otherwise difficult to detect until substantial and irreversible vision loss has occurred. Glaucoma is the third leading cause of blindness worldwide and the second leading cause of blindness in the USA.

Now, Duo Zhou and colleagues at the University of Medicine and Dentistry of New Jersey, Newark, have used statistical collinearity analysis to evaluate risk factors for OAG, and logistic regression models to identify a minimum set of such risk factors for prognosis and diagnosis of the disease. Their study was based on more than 400 patients with subtle or severe vision problems who attended hospital. It reveals the relative risk of being a smoker, age, visual "field test" results, presence of a localized notch or thinning of the neuroretinal rim identified during standard eye examination, cup to disk ratio (a measure of restriction of the optic nerve at the back of the eye) and other factors.

The data are complex and separating out predictors from diagnostic factors was difficult, the team admits. However, they suggest that family history, medical history, current medications, geographic location, visual field test and ocular examination must all be considered in diagnosis and prognosis for OAG. They have excluded certain factors from the OAG prognosis: gender, race, family history of glaucoma, diabetes mellitus, hypercholesterolemia, thyroid disease, migraine, Reynaud's disease and myopia as these have no direct effect on OAG development.

As revealed in the analyses, the odds of developing OAG will be increased by 91% with an increase in the Cup-to-Disc ratio of 0.1. Risk increases by 3% annually by age but decreases by 31% for every dB increase of mean deviation of Humphrey visual field. The odds of developing OAG will be 4.36 higher for patients with abnormal Humphrey visual filed overall test, 7.19 higher in patients with localized notch or thinning of the neuroretinal rim. Interestingly, patients with a smoking history seem to be less likely to develop OAG as compared to those with smoking history; although there are many smokers with OAG. Oddly, because of the location of the study, the team can also say that patients living in Atlantic/Quebec will be 73% less likely to develop OAG compared to their fellow Canadians in Ontario.


'/>"/>

Contact: Duo Zhou
duo.zhou@gmail.com
Inderscience Publishers
Source:Eurekalert

Related medicine news :

1. Study: Mechanomyography to be accurate in detecting nerves during minimally invasive spine surgery
2. FDG-PET/CT plays a definite role in detecting colorectal cancer recurrences
3. Detecting tumors faster
4. Sodium MRI gives new insights into detecting osteoarthritis, NYU researchers find
5. Effective methods for detecting early signs of tremor
6. Colorful brains, cooling lasers, disease-detecting lights and more
7. deCODE discovers genetic markers that improve the power of PSA testing for detecting prostate cancer
8. Detecting esophageal cancer with light
9. New molecular imaging technologies for detecting cellular processes
10. Toward a fast, simple test for detecting cholera rampaging in 40 countries
11. Penn study suggests another avenue for detecting Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Peoria, IL (PRWEB) , ... May 22, 2017 ... ... HealthCare, is part of a larger group investing in InsightRX, an early stage ... a patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund ...
(Date:5/21/2017)... FL (PRWEB) , ... May 20, 2017 , ... Pot. ... it, find it, review it, and share its attributes like never before. More than ... directory to connect cannabis enthusiasts to stores, strains, products – and for the first ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... longer than six months since you've seen a dentist, it's time for a ... and getting x-rays once per year. , Dental checkups are a relatively easy ...
(Date:5/19/2017)... ... May 19, 2017 , ... Springfield, Vermont-based law firm ... Titled " Ten Good Reasons To Hire An Experienced Personal Injury Attorney, " the ... an accident or injury. As the article says. if someone is injured due ...
(Date:5/19/2017)... ... 19, 2017 , ... As a groundbreaking surgeon on the frontline of prostate ... screenings. Early detection of the disease, he says, can make a world of difference. ... , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task Force and ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)...  Bayer announced today that the latest research from ... the 53 rd Annual Meeting of the American ... in Chicago . ... liver and thyroid cancers, as well as lymphomas, and ... trial of copanlisib in patients with relapsed or refractory ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: